Cervical cancer: cytological cervical screening in Iceland and implications of HPV vaccines

K. Sigurdsson
Cervical cancer: cytological cervical screening in Iceland and implications of HPV vaccines This paper reviews the Icelandic experience regarding the age‐specific effectiveness, optimal targeted age range and intervals in cervical cancer screening and the screening implications of the HPV16/18 vaccines. The background material is based on data from a screening programme with centralized records dating back to 1964, as well as from population‐based studies on the distribution of oncogenic HPV types in cancer and histologically verified CIN2‐3 lesions and from the Icelandic arm of the Future II trial with Gardasil^®. The findings confirm significant increased rates in the screened population of CIN2‐3, stage IA (microinvasive) cancer since 1979, mainly in the age group 20–34 years. These lesions start to accumulate within 3 years of a normal smear. Studies on the distribution of HPV types indicate that the marketed vaccines could lower the incidence of cancer and CIN2‐3 by about 67% and 53%, respectively, after taking into account reported cross‐protection. About 65% of women below 25 years of age had lesions related to the non‐vaccine types and after the last normal smear these cases accumulated at the same frequency as cases with vaccine‐included types. Cases with combined vaccine and non‐vaccine types accumulated at a slower rate. We conclude that screening should continue to start at age 20 years, with invitations at 2‐year intervals up to age 39 years and thereafter at 4‐year intervals up to age 65–69 years. Current data support the conclusion that the optimal age for catch‐up HPV vaccination should be considered in the context of sexual practices and the data do not support changes in the lower age limit or screening intervals for the vaccinated women.     

Estimation of disease severity in the NHS cervical screening programme. Part I: artificial cut‐off points and semi‐quantitative solutions

R. G. Blanks
Estimation of disease severity in the NHS cervical screening programme. Part I: artificial cut‐off points and semi‐quantitative solutions Objective: Current cytology and histology classifications are based on ordered categories and have a strong emphasis on providing information that decides a woman's management rather than the best estimate of disease severity. This two‐part paper explores the use of a quantitative approach to both cytology and histology disease severity measurements. Methods: In Part I the problem of artificial cut‐off points is discussed and a simple semi‐quantitative solution to the problem is proposed. This closely relates to the revised British Society for Clinical Cytology (BSCC) terminology. The estimates of disease severity are designed as extensions of the existing methods, with an emphasis on probability rather than certainty, as a more natural way of approaching the problem. Borderline changes are treated as categorical variables, but koilocytosis, mild, moderate and severe dyskaryosis, and ?invasive as quasi‐continuous and the disease severity estimated as a grade number (GN) with any value between 0–4 and the margin of error as a calculated grade range (CGR). Results: As an example, if the reader is unsure between moderate dyskaryosis (HSIL favouring CIN2) and mild dyskaryosis (LSIL favouring CIN1) they can register this uncertainty as a probability, such as 60%/40% moderate/mild. With 2 and 1 as the mid‐points of the grade numbers for moderate and mild dyskaryosis the GN value is ((60 × 2) + (40 × 1))/100 = 1.6. The CGR is 1.5 ? 0.4 to 1.5 + 0.6 = 1.1 to 2.1. The GN (CGR) estimate of disease severity is therefore 1.6 (1.1–2.1). In a similar manner the disease severity from all slides showing koilocytosis or dyskaryosis can be estimated as a number between 0 and 4 with an associated error. Histology can be treated in a similar way. Conclusions: This semi‐quantitative approach provides a framework more suitable for research and audit of disease severity estimates. It avoids the paradox inherent in the current systems using artificial cut‐points to produce categories whereby increasing agreement can only be achieved by losing information.     

GRPR在宫颈疾病中的表达及临床意义

目的：研究胃泌素释放肽受体（GRPR）在正常宫颈组织、宫颈上皮内瘤样病变（CIN）、宫颈癌中的表达,探讨GRPR在促癌发生和癌生长等方面的生物学功能。方法：采用免疫组化SP法检测GRPR在28例宫颈癌、51例宫颈上皮内瘤变和15例正常宫颈组织中的表达情况,其中以正常宫颈组织作为对照。结果：在正常宫颈和宫颈癌组织中,GRPR阳性表达率分别为20%和92.9%。GRPR在CINⅠ、CINⅡ、CINⅢ中阳性表达呈上升趋势,差别无统计学意义。宫颈癌组的不同临床分期、有无淋巴结转移组间比较,GRPR的阳性表达率均有显著性差异,并随病情严重程度的增加,阳性率增高,其表达强度呈显著正相关。结论：GRPR的过度表达与宫颈癌的发生、发展有关,是宫颈癌发生的早期事件,其检测可作为评估宫颈癌恶性程度、判断预后及指导治疗的重要参考指标。     

接头蛋白CIN85的结构与功能

CIN85与CD2AP构成了一个接头蛋白家族,在个体发育中担当重要角色并和多种疾病的病理机制相关。它们在功能结构域的序列上有很高的相似性,并具有细胞骨架蛋白的特点。近来研究表明CIN85在受体酪氨酸激酶(RTK)的内吞与降解、细胞凋亡、细胞局部黏附等许多生物学过程中发挥重要作用。     

The treatment of CIN: what are the risks?

The treatment of squamous cervical intraepithelial neoplasia is to remove or destroy the transformation zone (TZ). It is likely that no method of treatment is superior to another if it is performed properly and the limited available evidence supports this view. The significant advantages of excision (simplicity, cost, outpatient procedure, histological examination of the entire TZ) mean that treatment thresholds may have lowered over the last decade. Long-term pregnancy-related morbidity associated with excision has been reported recently. The evidence would suggest that this increase equates to a genuine increase in serious adverse outcome for cone biopsy but not large loop excision of the transformation zone (LLETZ). The available data also point to an increase in both incomplete excision and premature labour associated with the excision of large endocervical TZs. The clinical implications arising from this are firstly that women with large type 2 and 3 TZs need appropriate counselling before treatment and that the threshold for treating young women with mild abnormalities needs review.     

宫颈上皮内病变与HPV相关

目的了解辽宁省妇女生殖道人乳头瘤病毒（Human Papillomavirus,HPV）感染情况,研究辽宁省妇女宫颈上皮内病变与HPV感染的相关性。方法回顾性分析600例行核酸分子快速导流杂交基因芯片技术（Hybri Max）检测的患者,该600例患者均行薄层液基细胞学技术（Liguid-based cytologic teset,LCT）检查,有127例患者行病理活检,结合3种方法研究HPV感染与宫颈病变的相关性。结果导流杂交HPV-DNA检测结果与LCT结果相结合,600例患者中,感染HPV的阳性率分别为正常32%（92/288）,Asc-us42%（87/208）,LSIL53%（40/75）,HSIL86%（19/22）,癌100%（7/7）。导流杂交HPV-DNA检测结果与病理活检结果相结合,感染HPV的阳性率分别为：正常或慢性炎症36.17%（17/47）,CINⅠ66.67%（36/54）,CINⅡ-Ⅲ84.21%（16/19）,癌100%（7/7）,HPV感染阳性率随宫颈病变程度加重而明显升高。细胞学与组织学病理诊断符合率分别为LSIL72%（54/75）,HSIL86.36%（19/22）,SCC100%（7/7）。不同年龄阶段妇女感染HPV的阳性率依次为20-29岁46.76%（65/139）,30-39岁43.41%（79/182）,40-9岁40.48%（71/174）,50-59岁38.16%（29/76）,60-69岁37.50%（6/16）,70岁76.92%（10/13）。600例患者HPV感染总阳性率为40.83%（245/600）,在HPV21种亚型中,有19种亚型均被检测出,感染率最高的是HPV16 35.51%（87/245）,其它常见型别依次为HPV58,HPV6,HPV53,HPV18,HPV31,HPV52和cp8304。此外还发现高危型HPV16的感染率：正常或慢性炎症35.29%（6/17）CINⅠ33.33%（12/36）,CINⅡ-Ⅲ56.25%（9/16）,癌85.71%（6/7）,其感染率阳性率在各种程度的宫颈病变中占很大比重,也随宫颈病变的严重程度而增高,进一步论证了HPV16的高危性。结论辽宁省妇女HPV感染的主要亚型是HPV16,HPV58及HPV6.无论是与细胞学检测结果相结合还是与病理活检结果相结合,HPV感染阳性率均随宫颈病变程度的加重而增高。提示宫颈病变的防治重点应放在预防及治疗HPV感染。     

p16和bcl-2在宫颈上皮瘤样病变及宫颈癌中的表达

目的探讨p16和bcl-2表达产物在宫颈上皮瘤样病变及宫颈癌中表达的意义。方法对正常宫颈鳞状上皮、宫颈上皮内瘤变(CIN)和宫颈癌组织共69例,采用免疫组织化学EliVision法,对宫颈癌变过程中p16和bcl-2蛋白进行研究,将结果进行统计分析。结果p16蛋白在CIN中的表达高于正常宫颈上皮(P<0.01),在宫颈癌中的表达也高于正常宫颈上皮(P<0.01),且高于CIN中的表达(P<0.05);bcl-2蛋白在CIN中的表达高于正常宫颈上皮(P<0.01),在宫颈癌中的表达也高于正常宫颈上皮(P<0.01),但与CIN中表达无差异。p16和bcl-2两种蛋白在CIN和宫颈癌中的表达无明显差异。结论p16和bcl-2蛋白的表达与宫颈癌的发生有关,提示这两种蛋白有可能作为高危人群早期筛查的一种免疫组化指标。